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Objectives: Medication for the management of chronic obstructive pulmonary disease (COPD) may be 
delivered by a number of different inhaler devices. This study was undertaken to determine the clinical 
effectiveness of the Respimat® handheld inhaler device compared with other handheld inhaler devices for 
the delivery of medication in stable COPD.
Methodology: A systematic review of high-quality randomized controlled clinical trials comparing 
Respimat with other inhaler devices using the same medication was performed. Studies were searched 
for in the Cochrane Central Register of Controlled Trials as well as other relevant electronic databases. 
Manufacturers of inhaled COPD medication were also contacted for potential trials.
Results: Seven studies of high methodological quality with 3813 participants were included in the review. 
Three trials used Handihaler® as the comparator inhaler, three used a   chlorofluorocarbon metered-dose 
inhaler (CFC-MDI), and one trial used a hydroflouroalkane (HFA)-MDI. When Respimat was compared 
with Handihaler, the following reported outcomes were not significantly different: trough forced expira-
tory volume in 1 second (FEV1) (weighted mean difference [WMD] 0.01 L; P = 0.14), trough forced vital 
capacity (FVC) (WMD 0.001 L: P = 0.88), peak FEV1 (WMD 0.01 L: P = 0.08), peak FVC (WMD 0.01 L: 
P = 0.55), morning peak expiratory flow rate (PEFR) (WMD 5.06 L/min: P = 0.08), and evening PEFR 
(WMD 4.39 L/min: P = 0.15). Furthermore, there were no differences when Respimat was compared with 
Handihaler for risk of exacerbations (relative risk [RR] 0.94: P = 0.81), dry mouth (RR 1.57: P = 0.34), 
or nasopharyngitis (RR 1.42: P = 0.22). For Respimat compared with CFC-MDI, the only outcome for 
which data were available for meta-analysis was exacerbations, which were not significantly different (RR 
1.20: P = 0.12). In addition, five trials with 2136 patients showed that there was no difference in risk of 
exacerbations or nasopharyngitis when Respimat was compared with all other handheld inhaler devices (RR 
1.18: P = 0.13 and RR 1.33: P = 0.19, respectively). None of the clinical outcome measures reported was 
significantly different when the same, higher, or lower doses of medication were used in the inhaler devices 
being compared. Unfortunately, none of the included trials reported mortality as an outcome measure.
Conclusions: Evidence from high-quality trials published to date suggests that the   Respimat inhaler 
does not provide any additional clinical benefit to that provided by other inhaler devices in the manage-
ment of COPD. Although in vitro studies have reported differences between the Respimat inhaler device 
and other handheld devices, we found no difference in any clinical outcome measures, including lung 
function and adverse events. Although recent reports have highlighted concerns of increased mortality 
with the Respimat inhaler device, none of the included trials reported mortality as an outcome. Only a 
small number of trials reported data that could be used in this systematic review, and a limited number of 
studies have been published that compare Respimat with other inhaler devices using the same drug and 
strength. Therefore, further trials comparing Respimat with other handheld inhaler devices using the same 
drug and dose are required before firm conclusions can be drawn. The concern with increased mortality 
with Respimat use should be investigated urgently.
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Background
Respimat® Soft Mist™ Inhaler (Respimat; Boehringer 
Ingelheim, Germany) is a handheld inhaler device similar 
in size to the standard pressurized metered-dose inhaler 
(MDI). Compared with other inhaler devices currently 
available, Respimat has a number of benefits from the patient’s 
perspective.1,2 Respimat is simple to coordinate, and the 
delivered dose is independent of inspiratory effort. Respimat 
uses mechanical energy (via means of a spring) to generate a 
fine, slow-moving mist from an aqueous solution.3   Medication 
is stored as a solution in the aluminum drug cartridge, with a 
double-walled plastic collapsible bag that contracts as the solu-
tion is used. Actuation of the   Respimat dose release utilizes the 
mechanical energy from the spring to force the metered drug 
solution through channels, producing two fine jets of liquid 
at the outlet that converge at a predetermined angle to form 
the aerosol cloud.4 This cloud contains an aerosol with a fine 
particle fraction smaller than 5.8 µm, which has been shown 
in laboratory studies to be at least twice as high as most MDIs 
and dry powder inhalers.5 This should mean that a higher pro-
portion of the emitted dose is delivered to the lungs and less to 
the oropharynx with a Respimat inhaler compared with other 
inhaler devices.6 The “soft mist” moves more slowly and has a 
more prolonged duration than the aerosol cloud from an MDI. 
Hochrainer et al have compared Respimat aerosol velocity and 
spray duration with those of chlorofluorocarbon (CFC)-MDIs 
and hydroflouroalkane (HFA)-MDIs.5 The aerosol velocity 
from Respimat was between one-sixth and one-tenth that 
from the CFC- and HFA-MDIs. The mean velocity of the 
aerosol cloud measured at a 10 cm distance from the nozzle 
was 0.8 m/s for Respimat and 2.0–8.4 m/s for MDIs, and the 
mean duration was 1.5 s and 0.15–0.36 s, respectively.5
In vitro studies using Respimat have shown that in terms 
of access to the airways, 62% of the delivered dose contains 
particles that are 5.8 µm, which suggests that this fraction is 
approximately 2.5 times higher than that for most MDIs,7,8 
and the mean velocity of the soft mist is approximately five 
times lower.5,6 Both of these factors are important in the 
reduction of oropharyngeal deposition and an increase in lung 
deposition.7,8 Furthermore, in vitro studies have also suggested 
that a lower dose of tiotropium (5 µg and 10 µg) is needed 
in the Respimat device when compared with the Handihaler 
device (Boehringer Ingelheim, Ingelheim, Germany).6,9
The combination of smaller particle size, lower velocity, 
and longer duration of the aerosol cloud with the Respimat 
inhaler implies that there would be improved coordination of 
inhalation with actuation, higher lung deposition, and lower 
oropharyngeal deposition compared with MDIs. Studies pub-
lished to date tend to extrapolate in vitro nonclinical findings 
to clinical effectiveness.3,5,7,8,10,11 For example, an improvement 
in aerosol velocity, particle size, or lung deposition (nonclini-
cal measures) may be observed in a laboratory setting, but this 
does not   necessarily lead to improvements in lung function, a 
decrease in exacerbations, or improvements in quality of life 
  (clinical measures), as these parameters need to be measured 
directly in a clinical (trial) setting. Many of the studies con-
ducted to date have compared the Respimat inhaler with other 
handheld inhaler devices using various devices and combina-
tions of drug and strengths. Some studies have included half 
of the dose of drug in the Respimat inhaler when compared 
with another device, making the assumption that the Respi-
mat inhaler is twice as efficacious as the comparator.2,12–15 
To eliminate the influence of drug and dose, it is important 
to use the same drug and dose when comparing two inhaler 
devices. Only a handful of studies have attempted to compare 
the   Respimat inhaler with other inhaler devices using the same 
drug and dose,16,17 with varying results. Recent studies18,19 have 
also reported concerns regarding increased mortality with the 
use of the Respimat inhaler device in patients with chronic 
obstructive pulmonary disease (COPD), and this could be due 
to the greater deposition of bronchodilator medication to the 
lungs of patients with COPD. Therefore, mortality, among 
other outcomes, will be investigated in the current study.
Objectives
The aim of the current study was to conduct a systematic 
review of high-quality randomized controlled trials to 
evaluate the effectiveness of the Respimat inhaler when 
compared with other handheld inhaler devices using the same 
drug in the management of stable COPD.
Methods
Types of studies
Only randomized controlled trials were considered for 
inclusion. Trials were laboratory, community, or hospital based 
and were of any duration involving patients with stable COPD. 
Cumulative dosing or single dose trials were considered for 
inclusion, but these were analyzed in a separate subgroup from 
longer-term studies. Studies had to compare the same medica-
tion in both the Respimat inhaler and the comparator inhaler 
(eg, Respimat containing tiotropium compared with Handihaler 
containing tiotropium). Devices compared would preferably 
use the same dose. However, studies that used different doses 
in devices and compared the closest match between doses used 
in devices were included in the review. The difference in dose 
was noted and a subgroup analysis conducted if heterogeneity International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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between the included studies for an outcome was evident. 
  Studies comparing Respimat with an active drug to another 
device using placebo were excluded from this review.
Types of participants
Studies were considered in patients who met internationally 
accepted criteria for the definition of COPD (eg, American 
Thoracic Society [ATS], British Thoracic Society [BTS], 
European Respiratory Society [ERS], or Global Initiative 
for Chronic Obstructive Lung Disease [GOLD] guidelines). 
Studies were also considered if they met a practical defini-
tion of chronic airflow obstruction in the appropriate clinical 
setting of older (.40 years), usually (ex-)smoking patients 
with a forced expiratory volume in 1 second (FEV1) ,70% 
and FEV1/forced vital capacity (FVC) ,70% of predicted or 
were diagnosed by a respiratory physician as having COPD. 
Whether or not patients were able to use a particular inhaler 
prior to study entry did not affect inclusion to that study. 
It was understood that all patients would likely undergo 
training in use of the inhaler for the study.
Types of interventions
Studies were considered that described the use of Respimat 
compared with any other handheld inhaler for the delivery of 
the same medication. Co-intervention and/or contamination 
(eg, from crossover design studies) that may have occurred 
were recorded where data were available, and sensitivity 
  analysis was conducted to test for robustness of treatment 
effect.
Types of outcome measures
Primary outcomes included mortality, lung function measure-
ments (eg, FEV1, FVC, peak expiratory flow rate [PEFR], 
functional residual capacity, and total lung capacity) and 
exacerbations (eg, hospital admissions, unscheduled primary 
care attendance).
Secondary outcomes included symptom scores, use of 
additional relief medication, use of inhaled or oral steroid 
requirements (maintenance, rescue), patient preference, 
adverse effects, measures of systemic bioavailability, 
subsidiary physiological measures (eg, 6- or 12-minute 
walks and arterial blood gases), and validated quality of life 
measures (eg, St George’s Respiratory Questionnaire).
Search strategy for identification  
of studies
The Cochrane Central Register of Controlled Trials was 
searched for studies as well as separate additional searches 
carried out on PubMed (1966–September 2010), EMBase 
(1980–September 2010), Medline (1950–Septemebr 2010), 
CINAHL (1982–September 2010), Current Contents 
(1998–September 2010), and the Web of Science (1898–
September 2010). Citations were reviewed without language 
restriction. To provide an inclusive search, all database 
searches were conducted without any limitations, and we 
used a single search term: “respimat”.
The reference lists of all included studies and review 
articles were checked in order to identify any further relevant 
citations not captured by electronic or manual searches. 
Authors of included trials were contacted for any other 
unpublished studies and to determine whether more data 
or clarification were required for their studies. In addition, 
pharmaceutical companies who manufactured inhaled COPD 
medication were contacted in order to obtain details of any 
further published or unpublished studies.
Selection of trials
Two reviewers independently reviewed the results of a com-
puterized search based on study title, abstract, and key words/
MeSH headings, and any potentially relevant articles were 
obtained in full. The full texts of all potentially relevant arti-
cles were reviewed independently by the same two reviewers 
to assess each study according to previously written criteria. 
Written criteria included: 1) trials of a single or combina-
tion drug delivered by Respimat versus any other handheld 
inhaler device in stable COPD, 2) randomized controlled trial, 
3) patients with COPD diagnosed according to established 
internationally accepted guidelines (eg, GOLD, BTS, ATS, 
ERS) or by using a practical and objective definition of 
COPD, and 4) laboratory- or community-based study of any 
duration using the same drug in the devices being compared. 
Agreement between the two reviewers on inclusion of studies 
was complete. In all cases, disagreements about inclusion of 
a study were resolved by consensus. Details of trial selection 
and reasons for exclusion are shown in Figure 1.
Trial quality assessment
A methodological quality assessment of included trials was 
performed using the following criteria. Firstly, using the 
Cochrane Collaboration20 approach for the assessment of 
allocation concealment, all trials were scored according to the 
following grades: Grade A: adequate concealment, Grade B: 
uncertain, Grade C: clearly inadequate concealment, and 
Grade D: not used.
In addition, each study was assessed using the 0- to 5-point 
scale described by Jadad et al21 and summarized as follows:International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Potentially relevant abstract identified
and screened for retrieval (n = 241)
RCTs included in meta-analysis (n = 7)
Trials retrieved for more detailed evaluation
(n = 52)
Potentially appropriate RCTs to be
included in the meta-analysis (n = 8)
Trials/abstracts excluded as not relevant
(n = 189) 
RCTs withdrawn by outcome, with reason
(n = 0)
RCTs with usable information by outcome: 
Trough FEV1     n = 3 
Peak FEV1       n = 2 
Trough FVC       n = 3 
Peak FVC       n = 2 
Morning PEFR                      n = 2 
Evening PEFR                       n = 2 
Exacerbations       n = 3 
Dry mouth       n = 3 
Diarrhea        n = 1 
Nasopharyngitis                     n = 2 
RCTs excluded from meta-analysis:
ongoing trials (n = 1)
Trials excluded with reason (n = 44) 
Study did not use same drug          n = 14 
Not an RCT                    n = 19 
Cumulative dosing study                n = 3 
Not COPD patients                n = 8 
Figure 1 Results of the search for trials and reasons for excluding studies.
Abbreviations: COPD, chronic obstructive pulmonary disease; Fev1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEFR, peak expiratory flow rate; 
RCT, randomized controlled trial.
1.  Was the study described as randomized (1 = yes; 
0 = no)?
2.  Was the study described as double blind (1 = yes; 
0 = no)?
3.  Was there a description of withdrawals and dropouts 
(1 = yes; 0 = no)?
4.  Was the method of randomization well described and 
appropriate (1 = yes; 0 = no)?
5.  Was the method of double blinding well described and 
appropriate (1 = yes; 0 = no)?
Deduct one point if methods for randomization or 
blinding were inappropriate.
Data extraction
Details of each included trial characteristic were extracted 
and are shown in Table 1. All standard errors (SE) were International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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converted to standard deviations (SDs) using the following 
equation: SE × square root (SQRT) of N. For trials that only 
reported 95% confidence intervals (95% CI) instead of SD 
or SE, the SD was estimated using the following equation: 
[(higher 95% CI - mean)/1.96] × (SQRT of N).
Statistical considerations
Trials were combined for meta-analysis using the Cochrane 
Collaboration systematic review software (Review Manager 
4.3.2) from the Nordic Cochrane Centre, Rigshospitalet, 
Denmark.22 Two types of comparisons were conducted. 
Firstly, all studies comparing Respimat with another inhaler 
device were compared. Secondly, data from all devices 
compared with Respimat were combined to provide an 
overall comparison of all devices with Respimat. Mantel and 
Haenszel’s fixed effect model23 was used in the meta-analysis. 
Dichotomous outcomes such as exacerbations were assessed 
using relative risk (RR) (with 95% CI). Data from each of 
the continuous outcomes were analyzed as weighted mean 
differences (WMD with 95% CI).
If there was a sufficient number of included trials, subgroup 
analysis would have been carried out using medication dose, 
age, and disease severity. For each outcome measure, the null 
hypothesis that there is no heterogeneity between included 
randomized controlled trials was tested. Sensitivity tests were 
used to investigate any possible heterogeneity in the size of 
the measured response attributable to the subgroups identi-
fied previously and due to study quality. If sufficient studies 
were included, funnel plots were constructed for the outcome 
measures in order to test for possible publication bias.
Description of included trials
All seven included trials were either funded or supported 
by Boehringer Ingelheim, the manufacturer of Respimat 
inhaler device and producer of tiotropium and ipratropium. 
Contact with included study authors on repeated occasions to 
obtain additional data or clarification of trial results failed to 
produce any responses. Therefore, all data presented in this 
systematic review were obtained from those published in the 
manuscripts and available in the public domain.
Trial design and patient demographics
There were two laboratory-based trials,16,17 and the remaining 
five trials12,15,24–26 were based in either the community 
or hospital setting. There were four crossover-designed 
trials16,17,25,26 and three parallel-designed trials.12,15,24 Five 
of the trials were multicenter and/or multinational.12,15,24–26 
Patients included in the seven trials had the following values 
(range): age 46–70 years, FEV1 1.05–1.8 L, FVC 2.54–3.0 L, 
FEV1% reversibility 20%–51%, FEV1% predicted 37–52, 
FEV1/FVC% 42–55, and smoking pack-years 36–60 years.
Trial interventions, devices,  
and drug doses
Two trials were of single day duration. Brand et al16   compared 
fenoterol 50 µg plus ipratropium 20 µg in both the   Respimat 
and Handihaler in patients with poor MDI technique. 
Iacono et al17 used cumulative doses of ipratropium (one 
to eight puffs) inhaled at 50-minute intervals from one 
of the   following devices: Respimat 10 µg/puff, Respimat 
20 µg/puff, or CFC-MDI 20 µg/puff. No usable data were 
reported in these two trials.
Five trials that provided all of the data for the review 
included three trials that used Handihaler and two that used 
CFC-MDI. Caillaud et al24 used the Respimat inhaler with a 
range of doses of tiotropium (1.25 µg, 2.5 µg, 5 µg, 10 µg, 
and 20 µg, each dose given once daily using two puffs) 
compared with Handihaler 18 µg one capsule once daily 
for 21 days. A trial by van Noord et al26 also compared the 
Respimat containing tiotropium 10 µg with the Handihaler 
with 18 µg of tiotropium for 4 weeks. Ichinose et al25 used 
Respimat with tiotropium 5 µg compared with Handihaler 
with tiotropium 18 µg one capsule daily for 4 weeks.
Kilfeather et al12 compared Respimat with CFC-MDI with 
both devices containing ipratropium 160 µg plus fenoterol 
400 µg daily for 12 weeks, and Zuwallack et al15 compared 
Respimat with CFC-MDI using varying doses, with the dose 
included in the review being Respimat ipratropium 20 µg plus 
salbutamol 100 µg and for the CFC-MDI ipratropium 36 µg 
plus salbutamol 206 µg for 12 weeks.
Methodological quality  
of included studies
The seven included trials were of high-quality design, as 
the majority of the trials went to great lengths to double 
blind the patients and researchers of the inhaler devices by 
using placebo devices. This double-dummy design ensured 
that patients handled study inhalers equally and prevented 
both the investigators and patients from differentiating 
active drug from placebo, despite the different physical 
appearance of the devices. Except for the Iacono et al17 trial 
scoring an ‘A’ for Cochrane study quality grading, all other 
trials scored a ‘B’, and when using the Jadad quality scale 
all   trials scored 5, indicating that all included trials were of 
high methodological quality.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of included trials
Study reference Participants’ characteristics at baseline Intervention
Brand et al16 Laboratory-based study in Germany. Four-day, four-way  
crossover study with 13 patients included (9M/4F),  
5 ex-smokers, and 8 smokers. Mean values: pack-years 46.9,  
age 61.6 years, Fev1 1.37 L, Fev1% 46.4, Fev1/FvC ratio 0.44
Respimat (FeN 50 µg and IB 20 µg) vs HFA-MDI (FeN  
50 µg and IB 20 µg). Study in patients with poor MDI  
technique receiving radio-labelled Berodual and  
measuring lung deposition by gamma scintigraphy
Caillaud et al24  Multicenter, parallel-group, dose-ranging study across  
15 centers in France. COPD patients (n = 202; 86% males,  
mean age 61 years
Respimat (TTB 1.25 µg vs 2.5 µg vs 5 µg vs 10 µg  
vs 20 µg) vs Handihaler 18 µg vs Respimat (placebo)  
vs Handihaler (placebo) for 3 weeks. Study drugs were  
administered once daily (two puffs via Respimat or one  
capsule via Handihaler). Doses chosen for inclusion in  
review were Respimat TTB 10 µg two puffs daily  
vs Handihaler TTB 18 µg one capsule daily
Iacono et al17  Three-period crossover trial involving 36 COPD patients.  
Mean values: age 52 years, duration of COPD 10 months,  
Fev1% 52.6, FvC% 72.1, Fev1/FvC% 59.4, Fev1 1.8 L, FvC  
3.0 L, and Fev1 reversibility 30.7%
Cumulative doses of IB for 1+1+2+4+8 puffs inhaled at 
50-min intervals from one of the following devices:  
Respimat 10 µg/puff, Respimat 20 µg/puff, and CFC- 
MDI 20 µg/puff. Doses chosen for inclusion in the  
review were Respimat 20 µg/puff vs CFC-MDI 20 µg/puff 
(320 µg/device, over 250 min) 
Ichinose et al25 Two-way/two-period crossover design conducted in  
27 outpatient centers in Japan. 134 COPD patients  
completed the trial, 98% were males, 77.1% were  
ex-smokers, and 66.9% had severe or very severe disease.  
Mean values: age 70.2 years, Fev1% 43.1, Fev1/FvC% 41.9,  
smoking pack-years 60.4, and time since diagnosis 5.8 years 
Respimat (TTB 5 µg, two puffs of 2.5 µg) plus  
Handihaler placebo capsule vs Handihaler (TTB 18 µg  
one capsule daily) plus Respimat placebo inhaler. All  
treatments were administered for 4 weeks then all  
patients entered a 4-week wash-out period and then  
restarted study treatment for a further 4 weeks  
receiving different (whichever) combination treatment  
not received in the first period 
Kilfeather et al12  Multicenter, parallel-group trial conducted in 92 centers in  
europe. During a 2-week run-in, all patients received  
Berodual CFC-MDI (IB 20 µg/FeN 50 µg per puff) two puffs  
four times daily, and patients who had an exacerbation  
were excluded from the study. 224 patients were in the  
Respimat group and the CFC-MDI group had 220. Mean  
values: age 62 years, pack-years 36–37, Fev1 1.15–1.17,  
Fev1% 40–41, Fev1/FvC% 55–56, and % of patients with  
Fev1 reversibility .15% 42–51 
Patients remaining after the 2-week run-in period  
were randomized into one of five treatments: Respimat 
IB 10 µg/FeN 25 µg one puff, Respimat IB 20 µg/ 
FeN 50 µg one puff, CFC-MDI IB 20 µg/FeN 50 µg 
two puffs, Respimat placebo one puff, or CFC-MDI 
placebo two puffs. All treatments were administered 
four times daily. Doses chosen for inclusion in the 
review were Respimat IB 20 µg/FeN 50 µg one puff 
(total dose/day IB 80 µg/FeN 200 µg) vs CFC-MDI IB  
20 µg/FeN 50 µg two puffs (total dose/day IB 160 µg/ 
FeN 400 µg)
van Noord et al26  Multicenter, double-blind, crossover study. 205 COPD  
patients with 147 males, 128 ex-smokers, and COPD  
diagnosis of 10 years. Mean values: age 64 years, pack-years  
51, Fev1 1.05 L, Fev1% 37, FvC 2.54 L, Fev1/FvC% 42,  
Fev1 reversibility 19.9%
Respimat (TTB 5 µg, two puffs of 2.5 µg) plus  
Handihaler placebo capsule vs Respimat (TTB 10 µg, 
two puffs of 5 µg) plus Handihaler placebo vs  
Handihaler (TTB 18 µg one capsule daily) plus Respimat   
placebo inhaler vs Respimat placebo and Handihaler  
placebo. All treatments were administered for 4 weeks  
then all patients entered a 4-week wash-out period.  
This was a 4-week treatment period study with a 
4-week washout between each treatment. Doses 
chosen for inclusion in review were Respimat  
TTB 10 µg vs Handihaler 18 µg
Zuwallack et al15  Multinational (13 countries) multicenter (179) parallel trial. 
Following a 2-week run-in, 1480 patients were recruited  
and 1460 were evaluable. Mean age was 64.1 years; 65.4%  
of patients were male and 89.0% were white. The mean  
duration of COPD was 8.4 years. Current smokers  
(n = 600) or ex-smokers (n = 860) with a mean Fev1% of  
41.4, FvC 2.6 L, mean Fev1/FvC% of 44.8, smoking pack- 
years 51–52 years, Fev1 reversibility 0.217–0.216 L
Respimat (IB 20 µg and SAL 100 µg) vs CFC-MDI  
(IB 36 µg and SAL 206 µg) vs Respimat (IB 20 µg). All  
treatments were administered four times daily. All  
treatments were administered four times daily for  
12 weeks. Doses chosen for inclusion in review were  
Respimat IB 20 µg and SAL 100 µg vs CFC-MDI  
IB 36 µg and SAL 206 µg
Abbreviations: CFC, chlorofluorocarbon; COPD, chronic obstructive pulmonary disease; FEN, fenoterol hydrobromide; FEV1, forced expiratory volume in 1 second; FvC, 
forced vital capacity; HFA, hydrofluoroalkane; IB, ipratropium bromide; MDI, metered-dose inhaler; SAL, salbutamol; TTB, tiotropium bromide.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Results
A search of several databases identified 241 abstracts for pos-
sible inclusion in the review. On closer screening, 52 abstracts 
were selected and full-text articles retrieved. Closer exami-
nation of the 52 full-text articles excluded 45 as not being 
appropriate, and the remaining seven studies12,15–17,24–26 with 
3813 participants were included in the review.
Three trials24–26 compared Respimat with Handihaler, 
three trials12,15,17 compared Respimat with CFC-MDI, and 
one trial16 compared Respimat with HFA-MDI. However, 
only five trials12,15,24–26 reported data that could be used in the 
review, as the remaining two trials were either single-day16 
or single-dose17 studies. Outcome measures for which two or 
more trials contributed data are discussed here, and details 
of all outcomes measures in the review are listed in Table 2. 
Unfortunately, none of the included studies reported mortal-
ity as an outcome measure.
Respimat versus Handihaler
Three trials24–26 with 693 patients reported trough FEV1 
 ( Figure 2) and trough FVC (Figure 3). There was no 
difference in either trough FEV1 or trough FVC when 
  Respimat was compared with Handihaler (WMD 0.01 L: 95% 
CI 0.00 to 0.03, P = 0.14 and WMD 0.001 L: 95% CI -0.04 to 
0.03, P = 0.88, respectively). Two trials25,26 with 642 patients 
provided data on peak FEV1 and peak FVC. There was no 
difference in peak FEV1 or peak FVC when Respimat was 
compared with Handihaler (WMD 0.01 L: 95% CI 0.00 to 
0.03, P = 0.08 and WMD 0.01 L: 95% CI -0.02 to 0.04, 
P = 0.55, respectively).
Two trials24,26 with 425 patients contributed data toward 
morning and evening PEFR. There was no difference in 
morning or evening PEFR when Respimat was compared 
with Handihaler (WMD 5.06 L/min: 95% CI -0.69 to 10.72, 
P = 0.08 and WMD 4.39 L/min: 95% CI -1.54 to 10.31, 
P = 0.15, respectively).
Three trials24–26 with 715 patients provided data for 
rates of exacerbations and dry mouth (Figure 4). There was 
no   difference in risk of exacerbations or dry mouth when 
  Respimat was compared with Handihaler (RR 0.94: 95% 
CI 0.58 to 1.54, P = 0.81 and RR 1.57: 95% CI 0.62 to 3.97, 
P = 0.34, respectively). Two trials25,26 with 664 patients 
provided data for nasopharyngitis (Figure 4). There was no 
difference in risk of nasopharyngitis when Respimat was 
compared with Handihaler (RR 1.42: 95% CI 0.81 to 2.46, 
P = 0.22).
Respimat versus CFC-MDI
Two trials12,15 with 1421 patients showed no difference in risk 
of exacerbations when Respimat was compared with CFC-
MDI (RR 1.20: 95% CI 0.95 to 1.51, P = 0.12).
Respimat versus all other handheld 
inhaler devices
Five trials,12,15,24–26 three12,24,25 comparing the Handihaler 
with Respimat and two15,26 comparing the CFC-MDI with 
Table 2 Summary of effect sizes from outcomes reported in the included trials
Comparison/outcome WMD*/RR** 95% CI P value  No. of studies in  
outcome (participants)
Respimat versus Handihaler
Trough Fev1 (L) 0.01* 0.00 to 0.03 0.14 3 (693)
Trough FvC (L) 0.001* -0.04 to 0.03 0.88 3 (693)
Peak Fev1 (L) 0.01* 0.00 to 0.03 0.08 2 (642)
Peak FvC (L) 0.01* -0.02 to 0.04 0.55 2 (642)
Morning PeFR (L/min) 5.06* -0.69 to 10.72 0.08 2 (425)
evening PeFR (L/min) 4.39* -1.54 to 10.31 0.15 2 (425)
Adverse events
  exacerbations 0.94* 0.58 to 1.54 0.81 3 (715)
  Dry mouth 1.57* 0.62 to 3.97 0.34 3 (715)
  Diarrhea 0.33* 0.04 to 3.17 0.34 1 (294)
  Nasophryngitis 1.42* 0.81 to 2.46 0.22 2 (664)
Respimat versus CFC-MDI
Adverse events
  exacerbations 1.20 0.95 to 1.51 0.12 2 (1421)
  Nasophryngitis 1.21 0.62 to 2.38 0.58 1 (977)
Notes: *wMD; **RR.
Abbreviations: CFC-MDI, chlorofluorocarbon metered-dose inhaler; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FvC, forced vital capacity; PeFR, 
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  Respimat, could be combined to provide data for rates of 
exacerbations and nasopharyngitis. These five trials12,15,24–26 
with 2136 patients (Figure 5) showed that there was no 
difference in risk of exacerbations when Respimat was 
  compared with all other handheld inhaler devices (RR 1.18: 
95% CI 0.95 to 1.45, P = 0.13). Three trials15,25,26 with 1641 
patients provided data towards nasopharyngitis (  Figure 5), 
which showed that there was no difference in risk of 
nasopharyngitis when Respimat was compared with all 
other handheld inhaler devices (RR 1.33: 95% CI 0.87 to 
2.04, P = 0.19).
Data were not available for the following outcome 
  measures: mortality, symptom scores, use of additional 
relief medication, use of inhaled or oral steroid require-
ment   (maintenance, rescue), patient preference, measures of 
  systemic bioavailability, subsidiary physiological measures 
(eg, 6- or 12-minute walks and arterial blood gases), and vali-
dated quality of life measures. In addition, there was an insuf-
ficient number of included trials for any subgroup analysis.
None of the outcome measures reported was significantly 
different when the same, higher, or lower doses of medication 
were used in the inhaler devices being compared.
Discussion
Evidence from seven high-quality randomized controlled 
  trials with 3813 patients comparing Respimat with other 
inhaler devices produced similar outcomes. No differences 
were found in the following reported outcome measures: 
trough and peak FEV1, trough and peak FVC, morning 
and evening PEFR, or risk of exacerbations, drug mouth, 
or nasopharyngitis. No differences between devices were 
evident when the Respimat was compared with either the 
Handihaler or CFC-MDI or when a composite comparison 
of both devices was compared with Respimat (Figure 5). 
None of the included trials reported mortality as an outcome 
measure.
Only five of the trials reported data that could be used in 
the review. This and the limited number of studies   comparing 
Respimat with other inhaler devices using the same drug 
and the small number of included patients in trials do not 
permit firm conclusions to be drawn. Nevertheless, to date, 
evidence from these high-quality trials suggests that the 
Respimat inhaler device does not provide any additional 
clinical benefit to that provided by other inhaler devices, 
namely Handihaler and CFC-MDI, in the management of 
COPD. Contrary to comparative in vitro studies published 
by the manufacturer (sponsor) of Respimat inhaler device 
claiming superiority over other devices, to date, there is 
no clinical evidence to suggest that the Respimat inhaler 
device provides any greater benefit than that afforded by 
other inhaler devices. We have no reason to believe that the 
Respimat inhaler device would provide greater benefit than 
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any other handheld inhaler device. An extensive Cochrane 
systematic review published in 200227,28 strongly suggested 
that all handheld inhaler devices were clinically equivalent 
and that patients should be provided with devices that suit 
their purpose best. Since the publication of this key docu-
ment back in 2002, evidence from the current systematic 
review comparing Respimat with other inhalers confirms 
previous findings.
A comprehensive search strategy was developed for this 
review. Every effort was made to identify all of the relevant 
studies. No study was excluded due to language. Although 
several attempts were made to identify unpublished work, it 
is still possible that some studies have been missed. However, 
the small number of eligible studies was due not to restricted 
selection criteria but rather to the absence of identified   trials 
evaluating the Respimat inhaler device compared with 
other handheld inhaler devices using the same medication 
in COPD.
A common problem with conducting such a systematic 
review is that the included studies were designed as tests 
of the superiority of one device over another in which the 
null hypothesis was of equal efficacy. Such studies require 
fewer patients than those designed to test equivalence (null 
hypothesis that one device is superior to the other), and 
they also require predetermined limits of equivalence as in 
the Iacono et al trial,17 although this study was powered for 
superiority to test equivalence. Thus, the studies may have 
been underpowered. Failure to detect a difference should not 
necessarily imply equivalence, as trials designed to compare 
efficacy increase the chances of a type II error.
Another problem with such trials is that patients are 
  usually selected on the basis of being able to use a particular 
inhaler device as an inclusion criterion; therefore, the results 
would favour that particular device. Anecdotally, inhaler 
device familiarity may increase medication adherence, but 
COPD is among the conditions with the lowest levels of 
adherence.29 Nevertheless, inhaled medication adherence in 
COPD is a complex issue that involves a number of factors, 
which include the medication itself, the delivery device, 
the patient, and the healthcare professional.30 However, 
in the seven randomized controlled trials included in this 
review, previous patient familiarization with devices being 
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compared was not mentioned as a requirement for study entry. 
  Therefore, the limited results presented from these seven trials 
can be applied to most patients with stable COPD. Although 
adequate device use was not a requirement for entry into the 
study, we should assume that all patients recruited into these 
trials were taught to use the devices being compared.
Conclusion
There is currently no evidence to suggest that the Respimat 
inhaler device provides any additional clinical benefit to that 
provided by other handheld inhaler devices. Although the 
Respimat inhaler appears to be a more efficient device in 
vitro when compared with other devices, findings from such 
laboratory-based studies have failed to translate into any 
meaningful clinical outcomes. No differences were found 
in reported lung function or adverse events, and none of the 
included   trials reported mortality as an outcome. However, 
only a small number of trials reported data that could be used 
in this systematic review, and a limited number of   studies 
have been   published that compare Respimat with other 
inhaler devices using the same drug. Therefore, further trials 
comparing Respimat with other inhaler devices (including the 
Turbuhaler® [AstraZeneca, London, UK], HFA-MDI, Accu-
haler® [GlaxoSmithKline, Uxbridge, UK], Handihaler®, and 
Autohaler® [3M Pharmaceuticals, St Paul, MN]) using the 
same drug and dose are required before firm conclusions can 
be drawn. Until such evidence becomes available, all hand-
held inhaler devices should be considered clinically equiva-
lent, and patients should be provided with inhaler devices that 
best suit their needs and maximize inhaler medication adher-
ence. Furthermore, concerns reported in recently published 
studies regarding increased COPD   mortality risk with the 
use of Respimat inhaler device require urgent investigation.
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